Investigation into Select Medical Board for Potential Fiduciary Breaches
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Should l Buy SEM?
Source: Globenewswire
- Board Investigation: Brodsky & Smith law firm is investigating the Board of Directors of Select Medical Holdings Corporation for potential breaches of fiduciary duty related to the sale of the company for $16.50 per share, totaling an enterprise value of $3.9 billion, which may not provide fair value to shareholders.
- Transaction Value Dispute: The sale price is below Select Medical's 52-week high of $18.61 per share, raising concerns that the Board may have failed to act in the best interests of shareholders, thus questioning the fairness of the decision-making process.
- Legal Consultation Opportunity: Brodsky & Smith encourages shareholders of Select Medical to reach out for discussions on the legal implications of the investigation, indicating their willingness to provide no-obligation legal advice, which enhances shareholder awareness of their rights.
- Litigation Expertise: Brodsky & Smith has extensive experience in securities and class action lawsuits, having been appointed as lead counsel in numerous cases and successfully recovering millions for clients, demonstrating their capability in protecting shareholder interests.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SEM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SEM
Wall Street analysts forecast SEM stock price to rise
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 16.250
Low
17.00
Averages
18.75
High
21.00
Current: 16.250
Low
17.00
Averages
18.75
High
21.00
About SEM
Select Medical Holdings Corporation operates critical illness recovery hospitals, rehabilitation hospitals, and outpatient rehabilitation clinics in the United States. Its segments include Critical Illness Recovery Hospital, Rehabilitation Hospital, and Outpatient Rehabilitation. Critical Illness Recovery Hospital segment consists of hospitals designed to serve the needs of patients recovering from critical illnesses, often with complex medical needs. It operates the majority of its critical illness recovery hospitals as a hospital within a hospital (an HIH). Rehabilitation Hospital segment serves patients that require intensive physical rehabilitation care. Outpatient Rehabilitation segment consists of clinics that provide physical, occupational, and speech rehabilitation services. It operates around 105 critical illness recovery hospitals in 29 states, 36 rehabilitation hospitals in 14 states, and 1,922 outpatient rehabilitation clinics in 39 states and the District of Columbia.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
- Insider Trading Investigation: Halper Sadeh LLC is investigating Select Medical Holdings Corporation's sale to a consortium of executives and directors for $16.50 per share, which may infringe on shareholder rights.
- Shareholder Rights Protection: The sale of Farmer Brothers Coffee Co. at $1.29 per share prompts Halper Sadeh LLC to encourage shareholders to reach out to understand their rights and options, ensuring their interests are safeguarded.
- Shareholder Relief Measures: Texas Mineral Resources Corp. is selling for 3,823,328 shares of USA Rare stock, and Halper Sadeh LLC may seek increased compensation and additional disclosures to protect shareholder interests.
- Legal Fee Arrangement: Halper Sadeh LLC offers legal services on a contingency fee basis, meaning shareholders do not incur out-of-pocket legal fees, ensuring all shareholders can access legal support.
See More
- Acquisition Proposal Investigation: Former Louisiana Attorney General Charles C. Foti and his law firm Kahn Swick & Foti are investigating the acquisition proposal of Select Medical Holdings Corporation, led by a consortium of Select Medical executives and directors.
- Shareholder Return Analysis: Under the proposal, shareholders of Select Medical will receive $16.50 in cash per share, and the investigation aims to assess whether this price is adequate or undervalues the company.
- Legal Rights Consultation: KSF encourages shareholders who believe the transaction undervalues the company to contact them for legal advice, ensuring that shareholder rights are protected.
- Company Background Information: Select Medical Holdings Corporation holds a significant position in the healthcare industry, and the outcome of this investigation could impact its future market performance and shareholder confidence.
See More
- Shareholder Rights Investigation: Halper Sadeh LLC is investigating Select Medical Holdings Corporation's sale to a consortium led by executives for $16.50 per share in cash, potentially infringing on shareholder rights.
- Cash Acquisition Analysis: Clearwater Analytics Holdings, Inc. is being sold for $24.55 per share in cash to Permira and Warburg Pincus, with Halper Sadeh LLC possibly seeking increased consideration or other remedies to protect shareholder interests.
- FONAR Corporation Transaction: FONAR Corporation's sale involves Class B and Class C common stock at $19.00 and $6.34 per share, respectively, with Halper Sadeh LLC representing shareholders to seek a higher transaction price.
- Legal Service Commitment: Halper Sadeh LLC offers legal services on a contingency basis, ensuring no upfront costs for clients, aiming to assist investors affected by securities fraud and corporate misconduct in asserting their rights.
See More
- Earnings Beat Expectations: Ingram Micro reported a quarterly adjusted EPS of 96 cents, surpassing the analyst consensus estimate of 88 cents, indicating strong profitability and boosting investor confidence.
- Sales Missed Targets: Despite the positive EPS, the company's quarterly sales were $14.878 billion, falling short of the analyst consensus of $14.073 billion, reflecting challenges in market demand that could impact future growth.
- Stock Price Surge: Following the earnings report, Ingram Micro's shares jumped 11.8% to $23.87, demonstrating a positive market reaction to the company's profitability, potentially attracting more investor interest.
- Overall Market Decline: While Ingram Micro performed well, the broader market saw a decline, with the Dow Jones index dropping over 1,100 points on Tuesday, indicating volatility in market sentiment that could negatively affect other stocks.
See More
- Board Investigation: Brodsky & Smith law firm is investigating the Board of Directors of Select Medical Holdings Corporation for potential breaches of fiduciary duty related to the sale of the company for $16.50 per share, totaling an enterprise value of $3.9 billion, which may not provide fair value to shareholders.
- Transaction Value Dispute: The sale price is below Select Medical's 52-week high of $18.61 per share, raising concerns that the Board may have failed to act in the best interests of shareholders, thus questioning the fairness of the decision-making process.
- Legal Consultation Opportunity: Brodsky & Smith encourages shareholders of Select Medical to reach out for discussions on the legal implications of the investigation, indicating their willingness to provide no-obligation legal advice, which enhances shareholder awareness of their rights.
- Litigation Expertise: Brodsky & Smith has extensive experience in securities and class action lawsuits, having been appointed as lead counsel in numerous cases and successfully recovering millions for clients, demonstrating their capability in protecting shareholder interests.
See More
- Acquisition Agreement: Select Medical Holdings Corporation announced it will be acquired by a consortium led by Robert A. Ortenzio and Martin F. Jackson for $16.50 per share, valuing the company at approximately $3.9 billion, indicating strong market confidence in the deal.
- Significant Premium: The acquisition price represents an 18% premium over the unaffected share price as of November 24, 2025, and a 25% premium over its 90-day average closing price, reflecting the consortium's confidence in Select Medical's future prospects.
- Management Continuity: The deal was unanimously approved by Select Medical's independent board, with Ortenzio and Jackson opting to roll over their equity into the new parent company rather than cash out, demonstrating management's commitment to the company's future.
- Operational Stability: Select Medical will continue to operate normally during the merger process, with the current management team expected to remain in place, and existing debt will remain outstanding, simplifying the financing for the transaction.
See More










